{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:14:20Z","timestamp":1785572060503,"version":"3.56.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaci.2021.03.016","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T13:35:01Z","timestamp":1616247301000},"page":"1997-2008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["What is the contribution of IgE to nasal polyposis?"],"prefix":"10.1016","volume":"147","author":[{"given":"Claus","family":"Bachert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.03.016_bib1","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/ijms18061328","article-title":"dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies","volume":"18","author":"Palomares","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2021.03.016_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12016-018-8710-3","article-title":"IgE-mediated food allergy","volume":"57","author":"Anvari","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib3","doi-asserted-by":"crossref","unstructured":"Chinthrajah RS, Galli SJ. Omalizumab in \u201cnon-IgE-mediated\u201d diseases. J Allergy Clin Immunol 2021;147:1207-8.","DOI":"10.1016\/j.jaci.2020.10.033"},{"key":"10.1016\/j.jaci.2021.03.016_bib4","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.016_bib5","first-page":"27","article-title":"Omalizumab: a monoclonal anti-IgE antibody","volume":"7","author":"Belliveau","year":"2005","journal-title":"Med Gen Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000070434","article-title":"Immunological and clinical changes in allergic asthmatics following treatment with omalizumab","volume":"131","author":"Noga","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib9","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2021.03.016_bib10","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin-hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease: a randomized trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib12","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/all.13586","article-title":"Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab","volume":"73","author":"Weller","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000507218","article-title":"Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020","volume":"181","author":"Maurer","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/000348940311200709","article-title":"Prevalence of nasal polyps in adults: the Skovde population-based study","volume":"112","author":"Johansson","year":"2003","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaci.2021.03.016_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nri2072","article-title":"New developments in FcepsilonRI regulation, function and inhibition","volume":"7","author":"Kraft","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib19","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.4049\/jimmunol.176.11.7008","article-title":"Different stabilities of the structurally related receptors for IgE and IgG on the cell surface are determined by length of the stalk region in their alpha-chains","volume":"176","author":"Kubota","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107725","article-title":"Human eosinophils express the high affinity IgE receptor, FcepsilonRI, in bullous pemphigoid","volume":"9","author":"Messingham","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2021.03.016_bib22","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/cea.13157","article-title":"FcepsilonRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy","volume":"48","author":"Berings","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib23","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4049\/jimmunol.172.2.1065","article-title":"CD23 trimers are preassociated on the cell surface even in the absence of its ligand, IgE","volume":"172","author":"Kilmon","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4049\/jimmunol.163.1.217","article-title":"Humoral response suppression observed with CD23 transgenics","volume":"163","author":"Payet","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/mi.2015.16","article-title":"Inhibition of CD23-mediated IgE transcytosis suppresses the initiation and development of allergic airway inflammation","volume":"8","author":"Palaniyandi","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib26","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.2500\/ajra.2015.29.4131","article-title":"Prevalence of nasal polyps and its risk factors: Korean National Health and Nutrition Examination Survey 2009-2011","volume":"29","author":"We","year":"2015","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1398-9995.2005.00688.x","article-title":"Prevalence of nasal polyposis in France: a cross-sectional, case-control study","volume":"60","author":"Klossek","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ije\/28.4.717","article-title":"Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study","volume":"28","author":"Hedman","year":"1999","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaci.2021.03.016_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoto.2018.4103","article-title":"Association of chronic rhinosinusitis with depression and anxiety in a nationwide insurance population","volume":"145","author":"Kim","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaci.2021.03.016_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.03.016_bib31","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0003489415576181","article-title":"Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps","volume":"124","author":"Chung","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaci.2021.03.016_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4193\/Rhino16.126","article-title":"The effect of endoscopic sinus surgery on quality of life and absenteeism in patients with chronic rhinosinuitis\u2014a multi-centre study","volume":"55","author":"Sahlstrand-Johnson","year":"2017","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2021.03.016_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.2012.02559.x","article-title":"Chronic rhinosinusitis and asthma: novel understanding of the role of IgE \u2018above atopy\u2019","volume":"272","author":"Bachert","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11882-019-0880-4","article-title":"Chronic rhinosinusitis with nasal polyps in older adults: clinical presentation, pathophysiology, and comorbidity","volume":"19","author":"Song","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2021.03.016_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025611","article-title":"Activation-induced cytidine deaminase (AID)-associated multigene signature to assess impact of AID in etiology of diseases with inflammatory component","volume":"6","author":"Mechtcheriakova","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2021.03.016_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/all.12054","article-title":"Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps","volume":"68","author":"Gevaert","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jaci.2020.01.027","article-title":"Formation of nasal polyps: the roles of innate type 2 inflammation and deposition of fibrin","volume":"145","author":"Takabayashi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib39","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jaci.2017.01.019","article-title":"Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation","volume":"139","author":"Gevaert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw4295","article-title":"Protein crystallization promotes type 2 immunity and is reversible by antibody treatment","volume":"364","author":"Persson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jaci.2021.03.016_bib41","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.molmed.2019.05.003","article-title":"Staphylococcus aureus orchestrates type 2 airway diseases","volume":"25","author":"Teufelberger","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib42","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2016.05.041","article-title":"Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania","volume":"138","author":"Wang","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaci.2008.07.008","article-title":"Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease","volume":"122","author":"Zhang","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2500\/ajra.2013.27.3922","article-title":"Inflammatory patterns in upper airway disease in the same geographical area may change over time","volume":"27","author":"Katotomichelakis","year":"2013","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib46","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0091-6749(97)80019-X","article-title":"IL-5 synthesis is upregulated in human nasal polyp tissue","volume":"99","author":"Bachert","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaci.2021.03.016_bib49","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.iac.2018.06.006","article-title":"Biomarkers in chronic rhinosinusitis with nasal polyps","volume":"38","author":"Workman","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2021.03.016_bib51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib52","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jaci.2019.02.001","article-title":"Broad IgG repertoire in patients with chronic rhinosinusitis with nasal polyps regulates proinflammatory IgE responses","volume":"143","author":"Shamji","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib53","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jaci.2018.10.011","article-title":"Elevated IgE M1 prime transcripts in nasal tissues in patients with nasal polyps and asthma","volume":"143","author":"Scheerens","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib54","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lary.24418","article-title":"Analysis of comorbidities and objective parameters in refractory chronic rhinosinusitis","volume":"123","author":"Batra","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2021.03.016_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1398-9995.2010.02448.x","article-title":"Mucosal tissue polyclonal IgE is functional in response to allergen and SEB","volume":"66","author":"Zhang","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib56","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jaci.2016.03.040","article-title":"The quest for autoreactive antibodies in nasal polyps","volume":"138","author":"De Schryver","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2021.03.016_bib58","first-page":"S22","article-title":"International Consensus Statement on Allergy and Rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2021.03.016_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMcp1800215","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"381","author":"Hopkins","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.anorl.2015.03.008","article-title":"Efficacy of tobramycin aerosol in nasal polyposis","volume":"132","author":"Bonfils","year":"2015","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.jaci.2021.03.016_bib61","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib62","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2021.03.016_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients\u00a0with\u00a0chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib64","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/lary.27815","article-title":"Endoscopic sinus surgery for type-2 CRS wNP: an endotype-based retrospective study","volume":"129","author":"Alsharif","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2021.03.016_bib65","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib66","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib67","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib69","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.03.016_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2020.08.066","article-title":"Continued safety\/efficacy of omalizumab in chronic rhinosinusitis with nasal polyps: an open-label extension study","volume":"125","author":"Gevaert","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib73","first-page":"4616","article-title":"Late breaking abstract\u2014add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study","volume":"56","author":"Hopkins","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.03.016_bib75","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1398-9995.2011.02617.x","article-title":"Can anti-IgE therapy prevent airway remodeling in allergic asthma?","volume":"66","author":"Rabe","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib77","first-page":"5249","article-title":"Effects of omalizumab therapy on allergic rhinitis: a pilot study","volume":"20","author":"Masieri","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaci.2021.03.016_bib78","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2021.03.016_bib79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"Adelroth","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib83","first-page":"856s","article-title":"A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma","volume":"40","author":"Garcia","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.03.016_bib84","doi-asserted-by":"crossref","first-page":"AB90","DOI":"10.1016\/j.jaci.2017.12.290","article-title":"Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids","volume":"141","author":"Bachert","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1398-9995.1997.tb04876.x","article-title":"Definition, prevalence and development of nasal obstruction","volume":"52","author":"Jessen","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib86","first-page":"220","article-title":"Prevalence of allergic rhinitis comorbidity with asthma and asthma with allergic rhinitis in China: a meta-analysis","volume":"37","author":"Shen","year":"2019","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib87","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0091-6749(99)70370-2","article-title":"Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey","volume":"104","author":"Leynaert","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib88","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5415\/apallergy.2011.1.3.157","article-title":"Overview on the pathomechanisms of allergic rhinitis","volume":"1","author":"Pawankar","year":"2011","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4168\/aair.2015.7.4.321","article-title":"Local immunoglobulin E in the nasal mucosa: clinical implications","volume":"7","author":"De Schryver","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2021.03.016_bib90","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib91","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/108854196778662255","article-title":"The clinical relationship of nasal polyps to asthma","volume":"17","author":"Larsen","year":"1996","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2021.03.016_bib92","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-018-0823-y","article-title":"Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study","volume":"19","author":"Philpott","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2021.03.016_bib93","first-page":"45","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib94","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01592-2019","article-title":"Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge","volume":"55","author":"Bachert","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.03.016_bib95","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jprot.2017.12.003","article-title":"Staphylococcus aureus controls interleukin-5 release in upper airway inflammation","volume":"180","author":"Bachert","year":"2018","journal-title":"J Proteomics"},{"key":"10.1016\/j.jaci.2021.03.016_bib96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/ACI.0b013e3282f4178f","article-title":"Role of staphylococcal superantigens in upper airway disease","volume":"8","author":"Bachert","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib97","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaci.2010.07.007","article-title":"Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma","volume":"126","author":"Bachert","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib98","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0091-6749(03)70044-X","article-title":"IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma","volume":"111","author":"Bachert","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib99","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaci.2012.05.012","article-title":"Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma","volume":"130","author":"Bachert","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib100","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00198-2019","article-title":"Sensitisation to staphylococcal enterotoxins and asthma severity: a longitudinal study in the EGEA cohort","volume":"54","author":"Sintobin","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.03.016_bib101","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3254094","article-title":"Omalizumab for severe asthma: beyond allergic asthma","volume":"2018","author":"Loureiro","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaci.2021.03.016_bib102","doi-asserted-by":"crossref","DOI":"10.5402\/2011\/195846","article-title":"Airway epithelium in atopic and nonatopic asthma: similarities and differences","volume":"2011","author":"Pillai","year":"2011","journal-title":"ISRN Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1939-4551-7-17","article-title":"New strategies with anti-IgE in allergic diseases","volume":"7","author":"Holgate","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2021.03.016_bib104","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/164_2016_65","article-title":"Anti-IgE and biologic approaches for the treatment of asthma","volume":"237","author":"Mitchell","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jaci.2021.03.016_bib105","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib106","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/JAA.S107982","article-title":"Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history","volume":"11","author":"Tabatabaian","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib107","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"Macglashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib108","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2045-7022-3-29","article-title":"Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells","volume":"3","author":"Chan","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jaci.2017.08.032","article-title":"Plasmacytoid dendritic cells drive acute asthma exacerbations","volume":"142","author":"Chairakaki","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jaci.2014.12.1866","article-title":"T-cell regulation during viral and nonviral asthma exacerbations","volume":"136","author":"Wegrzyn","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib112","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00751-2020","article-title":"Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3(+)Tregs","volume":"57","author":"Lopez-Abente","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.03.016_bib113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2021.03.016_bib114","first-page":"736","article-title":"Local specific IgE production in nasal polyps associated with negative skin tests and serum RAST","volume":"55","author":"Small","year":"1985","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011857","article-title":"Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)","volume":"6","author":"Niven","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaci.2021.03.016_bib117","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","article-title":"Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma","volume":"124","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib118","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1183\/13993003.01501-2015","article-title":"Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma","volume":"48","author":"Pillai","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.03.016_bib119","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1164\/rccm.202003-0783ED","article-title":"Does IgE have a role in aspirin-exacerbated respiratory disease?","volume":"201","author":"Busse","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000076832","article-title":"Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship","volume":"133","author":"Perez-Novo","year":"2004","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib121","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/ajra.2014.28.4054","article-title":"Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease","volume":"28","author":"Johns","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib122","doi-asserted-by":"crossref","first-page":"AB204","DOI":"10.1016\/j.jaci.2017.12.645","article-title":"Nasal polyp IgE and IgG4 levels are elevated in aspirin-exacerbated respiratory disease","volume":"141","author":"Buchheit","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib123","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jaci.2016.09.025","article-title":"Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease","volume":"139","author":"Cahill","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib124","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2500\/ajra.2009.23.3367","article-title":"Detection of Staphylococcus aureus in nasal tissue with peptide nucleic acid-fluorescence in situ hybridization","volume":"23","author":"Corriveau","year":"2009","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib125","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00405-016-4273-1","article-title":"Aspirin-exacerbated respiratory disease and current treatment modalities","volume":"274","author":"Sakalar","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaci.2021.03.016_bib126","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000353976","article-title":"Clinical significance of immunoglobulin E responses to staphylococcal superantigens in patients with aspirin-exacerbated respiratory disease","volume":"162","author":"Yoo","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib127","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2021.03.016_bib128","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib129","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/imr.12632","article-title":"The role and relevance of mast cells in urticaria","volume":"282","author":"Church","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2021.03.016_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014794","article-title":"IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2021.03.016_bib132","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2017.10.035","article-title":"IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria","volume":"142","author":"Schmetzer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib133","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7150\/thno.29902","article-title":"On the lipophilic nature of autoreactive IgE in chronic spontaneous urticaria","volume":"9","author":"Lakin","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jaci.2021.03.016_bib134","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1111\/all.14412","article-title":"IgM and IgA in addition to IgG autoantibodies against Fc\u03b5RI\u03b1 are frequent and associated with disease markers of chronic spontaneous urticaria","volume":"75","author":"Altrichter","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib135","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib136","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib137","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/all.13587","article-title":"Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria","volume":"73","author":"Cugno","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib138","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000350388","article-title":"Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients","volume":"161","author":"Hatada","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib139","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/all.13381","article-title":"In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional","volume":"73","author":"Altrichter","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib140","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib141","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/all.13547","article-title":"Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study","volume":"74","author":"Metz","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib142","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.7150\/thno.18304","article-title":"Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jaci.2021.03.016_bib143","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib144","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/cea.12687","article-title":"The response to nasal allergen provocation with grass pollen is reduced in patients with chronic rhinosinusitis with nasal polyposis and grass sensitization","volume":"46","author":"Calus","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib145","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jaci.2013.02.002","article-title":"Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis","volume":"131","author":"Tan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib146","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.2500\/ajra.2013.27.3929","article-title":"Chapter 16: Determining the role of allergy in sinonasal disease","volume":"27","author":"Settipane","year":"2013","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2021.03.016_bib147","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw6433","article-title":"Identification of a T follicular helper cell subset that drives anaphylactic IgE","volume":"365","author":"Gowthaman","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jaci.2021.03.016_bib148","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jaci.2004.07.013","article-title":"Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis","volume":"114","author":"Van Zele","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.03.016_bib149","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1097\/00005537-200410000-00027","article-title":"Immunoglobulin E to staphylococcal and streptococcal toxins in patients with chronic sinusitis\/nasal polyposis","volume":"114","author":"Tripathi","year":"2004","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2021.03.016_bib150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jprot.2017.01.008","article-title":"Characterization of human and Staphylococcus aureus proteins in respiratory mucosa by in\u00a0vivo- and immunoproteomics","volume":"155","author":"Schmidt","year":"2017","journal-title":"J Proteomics"},{"key":"10.1016\/j.jaci.2021.03.016_bib151","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1084\/jem.20020044","article-title":"Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists","volume":"195","author":"Mellor","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.03.016_bib152","doi-asserted-by":"crossref","first-page":"16477","DOI":"10.1074\/jbc.M705822200","article-title":"Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells","volume":"283","author":"Paruchuri","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2021.03.016_bib153","article-title":"Late breaking abstract\u2014IgE-FceR1 cross-linking impairs the capacity of plasmacytoid dendritic cells to induce in\u00a0vitro functional regulatory T cells which can be restored by omalizumab","volume":"54","author":"L\u00f3pez-Abente","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2021.03.016_bib154","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.4049\/jimmunol.162.9.5455","volume":"162","author":"Yamaguchi","year":"1999","journal-title":"J Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921004723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921004723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:31:41Z","timestamp":1758792701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921004723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":147,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0091674921004723"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.03.016","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the contribution of IgE to nasal polyposis?","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}